<DOC>
	<DOCNO>NCT01467518</DOCNO>
	<brief_summary>Dolutegravir ( DTG , GSK1349572 ) integrase inhibitor currently Phase 3 clinical development treatment HIV infection . As HIV-infected subject may also receive methadone opioid dependence , evaluation potential interaction DTG methadone warrant . The primary objective study determine whether concomitant administration DTG affect pharmacokinetics ( PK ) methadone . As secondary endpoint , PK DTG compare historical data . This study open-label subject receive DTG stable dos methadone . The study conduct one center Canada adult male female subject .</brief_summary>
	<brief_title>Methadone-Dolutegravir ( DTG - GSK1349572 ) Drug Interaction Study .</brief_title>
	<detailed_description>The study open label methadone- doltegravir ( DTG , GSK1349572 ) drug interaction study consist 2 period . Subjects must opiate-dependent HIV sero-negative stable dose methadone 14 day prior pre-screening . After meet eligible criterion , subject remain individual methadone dose 3 day period 1 . In period 2 , subject continue individual stable dose methadone receive 50 mg DTG every 12 hour 5 day . Pharmacokinetics collect Day 3 period 1 Day 5 period 2 . Safety measurement routine chemistry , haematology urinalysis . Pharmacodynamic parameter pupillometry opioid symptom questionnaire collect timepoints pharmacokinetics . Subjects discharge last PK sample collect . A follow-up visit occur 7-14 day last dose study drug . This study conduct one centre Canada .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator feel find unlikely introduce additional risk factor interfere study procedure . Subjects positive serology hepatitis B C may enter discretion investigator , evidence active disease hepatic impairment new diagnosis . Male female 18 65 year age inclusive , time signing informed consent . Subject enrol methadone maintenance program least 12 week prior Period 1 , Day 1 , expect continue program though duration study . Subject receive methadone QD regimen remain unchanged 14 day prior PreScreening Visit dose â‰¤200mg daily . A female subject eligible participate : Nonchildbearing potential define premenopausal female document ( self report history ) tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception follow visit . Body weight &gt; /=50 kg male &gt; /=45kg females BMI within range 18.0 33.0 kg/m2 ( inclusive ) . ALT , alkaline phosphatase bilirubin &lt; /=1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug screen . Drugs screen include amphetamine , barbiturate , cocaine , PCP . The subject positive prestudy alcohol screen . A positive test HIV antibody . Current use alcohol , investigator 's opinion , would compromise subject 's safety and/or compliance trial procedure , include subject likely experience withdrawal symptom upon abstinence . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Subjects use concurrent prohibit medication . ( see Section 9.2 , detail prohibit medication ) . Use common medication permit study list Section 9.1 ( permitted medication ) . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pomelo , exotic citrus fruit , grapefruit hybrid fruit juices 10 day prior first dose study medication . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , peptic ulceration , low upper GI bleeding , inflammatory bowel disease pancreatitis exclude . Subject inadequate venous access . History Gilbert 's disease . The subject 's systolic blood pressure screen visit outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . Exclusion criterion screen ECG list protocol . Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any clinically significant arrhythmia , clinically significant conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia . Heavy smoker ( e.g. , &gt; 20 cigarettes/day ) unable abstain least 8 hour require protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>methadone</keyword>
	<keyword>Opiate-dependent</keyword>
</DOC>